Research graph
References from Safety assessment of ambrisentan based on the FDA Adverse Event Reporting System. Local targets link to admitted publications; unresolved targets remain external evidence.
A global view of pulmonary hypertension.
10.1016/s2213-2600(15)00543-3 · 2016 · External reference
Pulmonary hypertension.
2017 · External reference
Pulmonary arterial hypertension.
10.1186/1750-1172-8-97 · 2013 · External reference
Pulmonary arterial hypertension: pathogenesis and clinical management.
10.1136/bmj.j5492 · 2018 · External reference
Ambrisentan: a review of its use in pulmonary arterial hypertension.
10.1177/1753465817696040 · 2017 · External reference
Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis.
10.1038/s41598-020-72960-1 · 2020 · External reference
Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
10.1517/14656560903061275 · 2009 · External reference
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
10.1016/j.jacc.2009.07.033 · 2009 · External reference
Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
10.1002/ppul.22555 · 2013 · External reference
Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
10.1136/annrheumdis-2019-216274 · 2020 · External reference
Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source.
10.1093/bib/bbab347 · 2021 · External reference
Data mining of the public version of the FDA Adverse Event Reporting System.
10.7150/ijms.6048 · 2013 · External reference
Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions.
10.2165/00002018-200528010-00002 · 2005 · External reference
Ambrisentan in portopulmonary hypertension: a multicenter, open-label trial.
10.1016/j.healun.2019.12.008 · 2020 · External reference
Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes.
2013 · External reference
The transition from ambrisentan to macitentan in patients with pulmonary arterial hypertension: a real-word prospective study.
10.3389/fphar.2021.811700 · 2022 · External reference
Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS).
10.3389/fcvm.2026.1712783 · 2026 · External reference
Ambrisentan therapy for pulmonary arterial hypertension.
10.1016/j.jacc.2005.04.050 · 2005 · External reference
Endothelin.
10.1124/pr.115.011833 · 2016 · External reference
Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention.
10.1161/01.cir.0000109139.69775.eb · 2004 · External reference
Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes.
10.1016/s0735-1097(00)00822-6 · 2000 · External reference
Understanding sorafenib-induced cardiovascular toxicity: mechanisms and treatment implications.
10.2147/dddt.s443107 · 2024 · External reference
The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species.
10.1016/j.lfs.2008.06.008 · 2008 · External reference
Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy.
10.1002/med.21280 · 2014 · External reference
Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?
10.1016/s0008-6363(00)00263-7 · 2001 · External reference
Theoretical framework and key considerations for time-to-onset analysis in spontaneous reporting systems.
10.1007/s40264-026-01677-3 · 2026 · External reference
The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance.
10.1371/journal.pone.0068938 · 2013 · External reference
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.
10.3389/fdsfr.2023.1323057 · 2024 · External reference
Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future.
10.1177/2042098620938595 · 2020 · External reference
Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database.
10.1139/cjpp-2024-0078 · 2025 · External reference
